Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

HAYWARD, Calif., June 27, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.The purpose of the PEARL-SC study was to identify an effective and safe dose for future phase 3 clinical studies and explore key inclusion criteria and clinical endpoints in an effort to maximize differentiation of blisibimod from currently available therapies.  The 200mg weekly subcutaneous dose of blisibimod demonstrated a strong trend in improved clinical response as early as week 16 (p= 0.14), at the primary endpoint (p=0.15) and throughout week 44 including a statistically significant improvement at week 20 versus placebo (p=0.02).

In a predefined phase 3 target population of severely ill, seropositive lupus patients, defined as SELENA-SLEDAI ≥10 and receiving background corticosteroid medication, a more pronounced effect was seen in the 200mg weekly dose group demonstrating a 13.8% treatment difference compared to placebo at 24 weeks.  In this subgroup, planned for phase 3 studies, separation of clinical response occurred as early as week 8 and was also sustained through week 44.  Results from the 200mg weekly group are presented in Table 1.

"The extensive data in the target severe population from our Phase 2 clinical program supports the initiation of a much smaller yet differentiated Phase 3 registration plan with the selected dose of blisibimod in patients with severe systemic lupus erythematosus.  We have prospectively demonstrated for the first time the possibility for a subcutaneously administered BAFF inhibitor to be used in the treatment of a severe lupus population.  The subgroup of severe pat
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 The Coalition of State Rheumatology ... regional professional rheumatology societies, today released the findings ... perceptions of biosimilars and the potential impact of ... Biosimilars are medicines that are highly similar, but ... different from generic medications in that it is ...
(Date:7/1/2015)... 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief operating ... business and financial update on Wednesday, July 8, 2015 at ... A live audio webcast of the presentation may be accessed ...
(Date:7/1/2015)... 2015 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... taking place in New York, NY ... Hotel. James Sapirstein , Chief ... business during his live presentation and will be available ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... HILLS, Calif., Sept. 15, 2011 HealthTech Capital, a ... emerging HealthTech market, announced today that it has closed ... from HealthTech Capital members in a Series B syndicated ... while Niveus Medical received $600,000 in a Series A ...
... Sept. 15, 2011 CarePoint Partners (CarePoint), a leading ... that it has acquired Mountain State Infusion Services (Mountain ... 14th acquisition in less than four years. CarePoint now ... and is one of the largest independent infusion therapy ...
Cached Medicine Technology:HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market 2HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market 3CarePoint Partners Expands Coverage in the Ohio Valley Region with Acquisition of Mountain State Infusion Services 2
(Date:7/1/2015)... ... July 01, 2015 , ... Ormco Corporation, a leading ... fifth annual Smile for a Lifetime Foundation (S4L) fundraising event held at the ... to supporting S4L in its mission to provide free quality orthodontic care to ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Renowned ... the dates for the 2016 Dallas Rhinoplasty Symposium . Set for March 6th ... , Designed to take participants from the basic training and fundamentals of nasal surgery ...
(Date:7/1/2015)... ... 2015 , ... The 28th annual Charity Horse Show hosted by the Mid-South ... 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will again benefit ... Elvis impersonator, a silent auction and concessions. , Horses and riders from around the ...
(Date:7/1/2015)... ... July 01, 2015 , ... Trevor L. Williams, DMD holds a ... continued at USF earning a Master’s degree in Microbiology. He graduated from the University ... American Dental Association, the Florida Dental Association and the Academy of General Dentistry. Dr. ...
(Date:7/1/2015)... ... 01, 2015 , ... Boar’s Head Brand®, one of the ... Independence Day celebrations with new takes on classic dishes. From chicken salad with ... any summertime get together. , “Celebrating with family, friends, and great food is ...
Breaking Medicine News(10 mins):Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 3
... that gets the heart pumping may reduce the risk ... starts, reported a Mayo Clinic study published this month ... aerobic exercise in preserving cognitive abilities and concluded that ... against dementia. The researchers broadly defined exercise as ...
... Sept. 7 (HealthDay News) -- A new study reveals ... persuade their victims to withdraw the accusations of abuse. ... phone conversations between 17 accused male abusers in a ... decided not to follow through on the charges against ...
... new three-year, $12 million grant from the Bill & Melinda ... (HSPH) effort to significantly improve maternal health in developing countries. ... the practice of public health and coordinator of the Dean,s ... the grant, HSPH will host the Maternal Health Task Force ...
... Houston - Today, Barretos Cancer Hospital (BCH) in Brazil ... Sister Institution network. In a signing ceremony at BCH,s ... Anderson provost and executive vice president, Raymond DuBois, M.D., ... allow the two institutions to build a number ...
... getting good exercise, according to a new North Carolina ... parks. Results from the study suggest that ... parents were less likely to engage in higher levels ... today,s parents, unfortunately. Many parents are worried about the ...
... as a result of the reforms that the Government of ... However, the raising of retirement age is the least prejudicial ... has analysed the effects that these changes will have on ... these effects would be if the reforms were solely limited ...
Cached Medicine News:Health News:Aerobic exercise may reduce the risk of dementia, Mayo Clinic researchers say 2Health News:Abusers May Play on Victims' Emotions to Get Charges Dropped 2Health News:Harvard School of Public Health awarded $12 million grant to improve global maternal health 2Health News:Barretos Cancer Hospital and MD Anderson sign sister institution agreement 2Health News:Helicopter parents can impede child’s ability to play 2Health News:Delaying retirement age -- least prejudicial solution 2Health News:Delaying retirement age -- least prejudicial solution 3
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: